AKUMS

Akums Drugs and Pharmaceuticals Balance Sheet

₹824.90+1.26%
Market cap
₹12,629 crore
P/E
43.3
P/B
3.81
ROE
8.0%
Dividend yield
0.36%

As of Mar 2022, Akums Drugs and Pharmaceuticals had total assets of ₹13,700 crore and borrowings of ₹1,200 crore, against shareholders' equity of ₹9,000 crore — a debt-to-equity ratio of 0.13. Borrowings rose 93.83% from Mar 2023.

Akums Drugs and Pharmaceuticals balance sheet

As at each financial year end, newest first. H1 = half-year.

Akums Drugs and Pharmaceuticals balance sheet (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital50028.6128.6130.6230.62
Reserves8,5006396311,8292,086
Borrowings1,20061956588.21192
Other liabilities3,5001,9242,2319621,924
Total liabilities13,7003,2673,5164,1135,447
Fixed assets6,5001,2121,3911,5641,650
Capital work in progress400100100100100
Investments2,5006537038231,089
Other assets4,3009801,0551,2341,634
Total assets13,7003,2673,5164,1135,447

Balance sheet ratios

Debt to equity
0.13

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Akums Drugs and Pharmaceuticals balance sheet — frequently asked questions

What is the total debt of Akums Drugs and Pharmaceuticals?

Akums Drugs and Pharmaceuticals reported borrowings of ₹1,200 crore as of Mar 2022, compared with ₹619 crore as of Mar 2023.

What is Akums Drugs and Pharmaceuticals' debt-to-equity ratio?

Based on the Mar 2022 balance sheet, Akums Drugs and Pharmaceuticals' debt-to-equity ratio is 0.13 — borrowings of ₹1,200 crore against equity capital and reserves of ₹9,000 crore.

What are Akums Drugs and Pharmaceuticals' total assets?

Akums Drugs and Pharmaceuticals' total assets were ₹13,700 crore as of Mar 2022, including fixed assets of ₹6,500 crore and investments of ₹2,500 crore.

Same Data For Peers

Trade Akums Drugs and Pharmaceuticals With ATS

Track AKUMS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.